Chowdhury Ratna, Rashid Wardah, Singh Taranpreet, Rehman Abdur, Daterdiwala Nida F, Mkosi Varaidzo, Limbu Bhumikala, Bukhari Syeda Alliza, Ramadhan Afif, Dabas Muath M, Shehryar Abdullah, Khan Ramadan
Internal Medicine, Saint James School of Medicine, Arnos Vale, VCT.
Internal Medicine, Khawaja Muhammad Safdar Medical College, Sialkot, PAK.
Cureus. 2024 Dec 17;16(12):e75902. doi: 10.7759/cureus.75902. eCollection 2024 Dec.
This systematic review evaluates the outcomes of direct-acting antivirals (DAAs) compared to interferon-based therapies in patients with chronic hepatitis C infection. DAAs consistently demonstrate higher sustained virologic response (SVR) rates and better safety profiles across various patient populations, including those with cirrhosis and treatment-experienced individuals. The studies included highlight the superior efficacy of DAAs, with fewer adverse events such as anemia and fatigue, making them more tolerable and suitable for long-term treatment. These findings reinforce the clinical importance of DAAs as the standard of care for managing hepatitis C virus (HCV), particularly in special populations. Although interferon-based therapies remain relevant in resource-limited settings, this review emphasizes the need for broader access to DAAs to improve global health outcomes and reduce HCV-related morbidity and mortality.
本系统评价评估了在慢性丙型肝炎感染患者中，直接抗病毒药物（DAAs）与基于干扰素的疗法相比的治疗效果。在包括肝硬化患者和有治疗经验的个体在内的各种患者群体中，DAAs始终表现出更高的持续病毒学应答（SVR）率和更好的安全性。纳入的研究突出了DAAs的卓越疗效，其贫血和疲劳等不良事件较少，使其更易于耐受且适合长期治疗。这些发现强化了DAAs作为管理丙型肝炎病毒（HCV）护理标准的临床重要性，特别是在特殊人群中。尽管基于干扰素的疗法在资源有限的环境中仍然适用，但本评价强调需要更广泛地获得DAAs，以改善全球健康结果并降低与HCV相关的发病率和死亡率。
